Hifu no kagaku
Online ISSN : 1883-9614
Print ISSN : 1347-1813
ISSN-L : 1347-1813
CLINICAL EVALUATION
Effectiveness of Infliximab in Severe Psoriasis: A Single Center Experience
Yuichiro ENDO, Hideaki TANIZAKI, Akihiro FUJISAWA, Atsushi OTSUKA, Gyohei EGAWA, Akiko ARAKAWA, Takashi NOMURA, Akihiko KITOH, Miki TANIOKA, Yumi MATSUMURA, Kenji KABASHIMA, Yoshiki MIYACHI
Author information
Keywords: infliximab, psoriasis arthropica, erythroderma psoriaticum, psoriasis, biologics
JOURNAL RESTRICTED ACCESS

2013 Volume 12 Issue 4 Pages 301-305

Details
Download PDF (764K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract
Background Infliximab is a monoclonal antibody for the treatment of moderate to severe psoriasis including psoriasis arthropica and erythroderma psoriaticum. Objectives To evaluate the effectiveness of infliximab in the treatment of severe psoriasis. Methods Presence of joint pain and Psoriasis Area and Severity Index (PASI) 90 response rate were set as the primary endpoints. Infliximab was administered to 11 patients as a 5mg/kg intravenous injection at the interval indicated in the official pharmaceutical reference. Results Initial PASI score was 23.0±17.1 (range 3.6-58.8). PASI score was significantly improved within two weeks (t=2.76, p=0.02). PASI 90 response was achieved in 64% of all cases. Joint pain was also improved soon after the first administration of infliximab. Conclusions Infliximab was revealed to be effective for the treatment of severe psoriasis including psoriasis arthropica and erythroderma psoriaticum.Skin Research, 12: 301-305, 2013
Content from these authors
© 2013 Meeting of Osaka Dermatological Association/Meeting of Keiji Dermatological Association
Previous article
Favorites & Alerts

Recently viewed articles
Predecessor

Skin research

Share this page
feedback
 Top